Home
Live Updates
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting : comparemela.com
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients
Related Keywords
United States ,
San Antonio ,
Texas ,
University Of Texas ,
America ,
American ,
Intravesical Cretostimogene Grenadenorepvec ,
Calmette Guerin ,
Cretostimogene Grenadenorepvec ,
Ambaw Bellete ,
Henryb Gonz ,
Bing Kung ,
Markd Tyson ,
Robert Svatek ,
Nasdaq ,
American Urological Association ,
Convention Center ,
Globe Newswire Cg Oncology Inc ,
Annual Meeting ,
Chief Operating Officer ,
Single Arm Study ,
High Risk ,
Unresponsive Non Muscle Invasive Bladder Cancer ,
Practice Changing Clinical Trials ,
Urologic Oncologist ,
Mayo Clinic ,
Central Daylight ,
Randomized Study ,
Clinical Trials ,
Texas Health Science Center ,
Papillary Only ,
Unresponsive Non Muscle Invasive Bladder ,
Non Muscle Invasive Bladder Cancer ,
Bacillus Calmette Guerin ,
North America ,
Private Securities Litigation Reform Act ,
Region ,
comparemela.com © 2020. All Rights Reserved.